MNMD
Mind Medicine (MindMed) Inc. [MNMD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MNMD Stock Summary
Top MNMD Correlated Resources
MNMD
Top 10 Correlated ETFs
MNMD
Top 10 Correlated Stocks
MNMD
In the News
MNMD Financial details
Company Rating
-
Market Cap
681.74M
Income
-98.4M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-2.44
Forward P/E
-
PEG
-0.38
P/S
-
P/B
1.79
P/C
-
P/FCF
-4.47
Quick Ratio
3.78
Current Ratio
3.85
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.52
EPS next Y
-
EPS next Q
-
EPS this Y
59.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
31.11%
-
-
-
-
SMA20
-3.32%
SMA50
-28.92%
SMA100
-21.24%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-58%
ROC
-0.8%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.41-12.22
52W High
-46.75%
52W Low
+219.5%
RSI
55.65
Rel Volume
0.86
Avg Volume
2.2M
Volume
1.9M
Perf Week
12.9%
Perf Month
-0.93%
Perf Quarter
5.45%
Perf Half Y
-3.91%
-
-
-
-
Beta
2.531
-
-
Volatility
0.2%, 0.53%
Prev Close
1.43%
Price
6.39
Change
0.79%
Company Profile
- Volume Average 2.2M
- Market Capitalization 681.74M
- Employee 57
- CEO Mr. Robert Barrow
- Headquarters Vancouver,BC,CA
- IPO Date 2016-11-15
-
Website
https://www.mindmed.co 
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
